All News

pregnant, pregnancy, mother, fertility

New Insights into Pregnancy Outcomes and Maternal-Fetal Health in Rheumatic Diseases

ACR Press Release

At ACR Convergence 2025, the American College of Rheumatology presents new research illuminating critical challenges and advances in pregnancy outcomes for women living with rheumatic diseases, including axial spondyloarthritis, antiphospholipid syndrome, and lupus.

Read Article
RheumNow Podcast square

Pre-ACR25 (10.24.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and info reports the day before ACR 2025

Read Article
RheumNow Podcast square

Bad Actor Cofactor (10.17.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports, discusses pediatric reports, pregnancy data, diet and nutrition and more.

Read Article
pregnant, pregnancy, mother, fertility

Pregnancy Management in Inflammatory Bowel Disease: A Global Consensus

Jack Cush, MD

Consensus guidance on the management of pregnancy in patients with inflammatory bowel disease (IBD) was simultaneously published in six international journals, including The American Journal of Gastroenterology.

Read Article
juvDM1.jpg

MSK Manifestations in Pediatric IBD

Jack Cush, MD

Arthritis and musculoskeletal (MSK) symptoms may accompany pediatric-onset inflammatory bowel diseases (pIBD) as an extra-articular intestinal manifestation, but may vary in presentation and clinical course.

Read Article
RheumNow Podcast square

Associations in Rheumatology (10.3.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal reports and important associations in rheumatology from the past week on RheumNow.com.

Read Article
ASAS recommends standardised reporting for 20 key outcomes in axSpA trials, 10 for all studies, 10 specific to DMARD trials. Formats include mean (±SD), mean change, and categorical thresholds for ASDAS, ASAS-HI, and extra-musculoskeletal manifestations. 85% of ASAS members https://t.co/VQwPaTRIOl

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Accdg to this retro analysis of their prospective cohort study from Toronto, 47 pts (10%) had D2M axSpA of whom 14 had tx-refractory dse. D2M pts - longer symptom duration; ⬆️ASDAS, BASDAI, BASMI, BASFI & ⬆️CRP 💡Consider non-dse factors in D2M pts #ACR25 @RheumNow Abs0547 https://t.co/MUUyyELbw8

Links:

sheila RHEUMarampa ( View Tweet)

Singla et al. In secukinumab phase 3 trials, fungal (inc candida) infections uncommon. 5.51 for sec vs 3.39 for PBO per 100PY. @RheumNow #ACR25 Abstr#585 https://t.co/g78zUsxD5a

Links:

Richard Conway RichardPAConway ( View Tweet)
Damen et al. 10-year follow-up of CRESPA study. Treatment withdrawl trial in early peripheral SpA. 38% in drug free remission. 82% in remission. @RheumNow #ACR25 Abstr#568 https://t.co/KOVW5pSbJg

Links:

Richard Conway RichardPAConway ( View Tweet)
DESIR cohort of early axSpA: ✳️Factors assoc w/ D2M axSpA - female sex, ⬆️ASDAS-CRP ⬆️BASFI ⬆️ASQOL at baseline. ✳️ Low prevalence of pts meeting D2M definition (15 pts - 8.4% bDMARD-treated) #ACR25 @RheumNow Abs0544 https://t.co/fBUh3myKcz

Links:

sheila RHEUMarampa ( View Tweet)
Ramiro et al. No significant differences seen between men and women in response to upadacitinib in AxSpA at week 14 or 52. Differs from data on TNFi/IL17i in this regard. Looks to me like men respond a bit quicker and better though... @RheumNow #ACR25 Abstr#589 https://t.co/2m7mrgcG0z

Links:

Richard Conway RichardPAConway ( View Tweet)
In a nationally representative NHANES sample, inflammatory back pain (IBP) was not associated with HLA-B27 positivity or elevated CRP, regardless of IBP criteria used (e.g., Berlin 8a: OR 0.88, p=0.876). IBP alone may be insufficient for identifying axSpA-related immunogenetic or https://t.co/82NjVU171z

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
AI-enhanced MRI integrating STIR and T1-weighted MRI with BME data reflecting both inflammatory and structural changes, enabling the AI model to predict clinical diagnoses of axSpA with accuracy of 82%. Successfully identified axSpA patients who did not meet the ASAS criteria for https://t.co/dLlGj0ZFpj

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
5–10% of axSpA [ts jave comorbid IBD. Southern Swedish study 152 (r- & nr-) axSpA pts found elevated fecal calprotectin (≥ 50 mg/kg) & this was assoc. w/ more damage w/ higher mSASSS values for all axSpA (adj OR 2.2) & in r-axSpA (adj OR 2.9) https://t.co/Hi1lE4so1r https://t.co/YYCGYYasfL

Links:

Dr. John Cush RheumNow ( View Tweet)
From the plenary to posters, RheumNow is your companion for ACR Convergence 2025. Expect: • KOL videos • Clinical trial highlights • Daily faculty recaps • Live streaming #ACR25 #Rheumatology #ClinicalTrials https://t.co/zZAwYINmC2
Dr. John Cush RheumNow ( View Tweet)
Metanalysis of whole-body cryotherapy (WBC) in Ankylosing spondylitis (AS) - 5 studies & 310 #AS pts. Temps (−60°C to −10°C) & duration (80 sec to 3 min) varied. WBC significantly mproved BASDAI (p<0.001), ASDAS ( 0.015), BASFI (0.006), & VAS pain (.005), but NOT CRP https://t.co/6Sj3bg096X
Dr. John Cush RheumNow ( View Tweet)
Axial involvement in PsA (axPsA)? study of 581 PsA pts (mean 45 yrs) found 31% w/ SpA-SI joint (SIJ) abnormalities on MRI (MRI-axPsA). MRI-axPsA pts had BM edema(69%), erosions (68%), fat lesions (58%). ~45% w/ Xrays, 29% met Xray mNY criteria for AS (38% +MRI). +MRI assoc w/ https://t.co/MRbs8G3MWq
Dr. John Cush RheumNow ( View Tweet)
Study of 246 axSpA (nraxSpA 82, r-axSpA 164) w/ Sxduration 26 yrs. axSpA had more comorbid Dz (^CCI) esp for uveitis (28 vs 1%), IBD (10 v 1%), PsO (10 v 3%)], CVD (7 v 3%), FM (12 v 3%). BUT NO DIFF between r-axSp & nraxSpA for comorbidities https://t.co/0ERLt083yq https://t.co/65x02ZFKTb

Links:

Dr. John Cush RheumNow ( View Tweet)
HLA-B27: still the most important genetic factor in axSpA susceptibility, but has lower frequency African American, South American & Middle Eastern pop. B27 discerns clinical subsets of SpA and PsA, particularly acute anterior uveitis or axSpA with psoriasis, https://t.co/S4s0NvuwNY
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×